Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Phase 1/2 Completed 50 enrolled Abramson Cancer Center at Penn Medicine

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.

Timeline

Start: 2014-10
Primary completion: 2021-10
Completion: 2021-10

Outcome

Missed primary endpoint

paper Progression-free survival does not meet the pre-specified threshold for the entire cohort PMID 35156519 ↗

Publications

Amaravadi RK. Clinical trial results show promise of targeting autophagy BRAF mutant melanoma. Autophagy. 2022 Jun;18(6):1470-1471. doi: 10.1080/15548627.2022.2038899. Epub 2022 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabrafenib	Small molecule	150 mg	Oral
Subject	Hydroxychloroquine	Small molecule	600 mg	Oral
Subject	Trametinib	Small molecule	2 mg	Oral